Remimazolam’s clinical application and safety: A signal detection analysis based on FAERS data and literature support
PLOS One · 22.08.2025 · 20 (8) · e0330769
DOI: 10.1371/journal.pone.0330769 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 22.08.2025. Verfasst von Gang Ye und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Medicine, Shaoxing People's Hospital, Shaoxing, China. Hauptthemen laut MEDLINE: Benzodiazepines, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study aimed to evaluate the adverse event profile of remimazolam, a novel ultra-short-acting benzodiazepine, with a focus on its safety in the respiratory, cardiovascular, and immune systems across diverse patient populations. We analyzed adverse event reports from the FAERS database over a defined period, performing signal detection using the proportional reporting ratio (PRR) and the reporting odds ratio (ROR), and contextualized the findings with a concurrent literature review. Remimazolam demonstrated a strong signal for hypoventilation. In the cardiovascular system, it was associated with serious adverse events, including cardiac and cardiorespiratory arrest, particularly in high-risk patients. Furthermore, we detected significant signals for severe hypersensitivity reactions, such as anaphylactic shock and laryngeal edema, while signals in other systems were less pronounced but remained clinically significant. Given that the study population was predominantly elderly, and considering the serious nature of the identified signals, its potential for adverse events necessitates vigilant monitoring. Future research should focus on clarifying risks within specific high-risk groups to establish optimized safety protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pain Medicine, Shaoxing People's Hospital, Shaoxing, China.
- Department of Internal Medicine, Shaoxing Yuecheng People's Hospital, Shaoxing, China.
ORCID-Profile: Qingbo Zhou
Zitieren
APA
Ye, G., Ding, L., & Zhou, Q. (2025). Remimazolam’s clinical application and safety: A signal detection analysis based on FAERS data and literature support. PLOS One, 20(8), e0330769. https://doi.org/10.1371/journal.pone.0330769
Vancouver
Ye G, Ding L, Zhou Q. Remimazolam’s clinical application and safety: A signal detection analysis based on FAERS data and literature support. PLOS One. 2025;20(8):e0330769. doi:10.1371/journal.pone.0330769
BibTeX
@article{Ye2025,
author = {Ye, Gang and Ding, Luqin and Zhou, Qingbo},
title = {Remimazolam’s clinical application and safety: A signal detection analysis based on FAERS data and literature support},
journal = {PLOS One},
year = {2025},
volume = {20},
number = {8},
pages = {e0330769},
doi = {10.1371/journal.pone.0330769}
}
EUVIMED